Suppr超能文献

[冠状动脉Palmaz-Schatz支架植入后抗凝血酶III、凝血酶原片段1+2及凝血酶-抗凝血酶III复合物的变化]

[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].

作者信息

Dittel M, Haushofer A, Spiel R, Halbmayer W M, Prachar H, Fischer M, Mlczoch J

机构信息

Medizinische Abteilung mit Kardiologie, Krankenhaus Lainz, Ludwig-Boltzmann-Institut für Herzinfarktforschung, Wien, Osterreich.

出版信息

Z Kardiol. 1995 Jan;84(1):22-9.

PMID:7863710
Abstract

To detect changes in the clotting parameters antithrombin III (AT III), prothrombin-fragment 1 + 2 (F 1 + 2) and thrombin-antithrombin-III-complex (TAT) after implantation of Palmaz Schatz stents, coagulation was monitored at standardized time points in 35 patients for 10 days. All patients were anticoagulated using a combination of heparin, phenprocoumon, and acetyl salicylic acid. Heparin therapy was guided by APTT levels (normal range 25-35 s), which were still within the therapeutic range (median 49.6 s (25%/75% percentiles 41.6/54.4) on day 10. Simultaneous oral anticoagulation was found to be effective on day 8 on average (INR median 2.24 (1.93/2.50)). The AT III activity dropped significantly (p < 0.0001) after a heparin loading dose of 15,000 IU during stenting. As the heparin dose was reduced on the following days, AT III levels increased significantly (p < 0.0001) during the observation time. There was a highly significant (p < 0.001) negative correlation between AT III and heparin levels. On days 4 and 5 F 1 + 2 values were significantly (p < 0.001 and p < 0.05) higher than on the day of stenting (median 1.07 (0.90/1.31) 1.13 nmol/l and 1.06 (0.85/1.23) nmol/l vs. 0.97 (0.69/1.15) nmol/l) and dropped during anticoagulation. F 1 + 2 levels showed a significant negative correlation (p < 0.0005) with APTT values. TAT values showed no significant changes during the observation period.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

为检测Palmaz Schatz支架植入后凝血参数抗凝血酶III(AT III)、凝血酶原片段1+2(F 1+2)和凝血酶-抗凝血酶III复合物(TAT)的变化,在35例患者中于标准化时间点监测凝血情况,持续10天。所有患者均联合使用肝素、苯丙香豆素和乙酰水杨酸进行抗凝治疗。肝素治疗以活化部分凝血活酶时间(APTT)水平(正常范围25 - 35秒)为指导,在第10天时其仍处于治疗范围内(中位数49.6秒(第25/75百分位数41.6/54.4))。同时口服抗凝治疗平均在第8天起效(国际标准化比值(INR)中位数2.24(1.93/2.50))。在支架置入期间给予15,000 IU肝素负荷剂量后,AT III活性显著下降(p < 0.0001)。在接下来的几天中,随着肝素剂量减少,观察期间AT III水平显著升高(p < 0.0001)。AT III与肝素水平之间存在高度显著的负相关(p < 0.001)。在第4天和第5天,F 1+2值显著高于支架置入当天(p < 0.001和p < 0.05)(中位数分别为1.07(0.9 / 1.31)、1.13 nmol/l和1.06(0.85 / 1.23)nmol/l,而支架置入当天为0.97(0.69 / 1.15)nmol/l),且在抗凝过程中下降。F 1+2水平与APTT值呈显著负相关(p < 0.0005)。在观察期内TAT值无显著变化。(摘要截选至250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验